Exemestane for early-stage ER-positive breast cancer

tamoxifen treatment for 5 years. On the other hand, postmenopausal women are offered 5-year monotherapy of AIs or tamoxifen. In consideration of higher treatment availability and better accessibility, tamoxifen and letrozole remain the standard treatment for early-stage breast cancer. Alongside endocrine therapy, chemotherapeutic ................
................